Emkay's latest report downgrades Dr. Reddy's Labs, citing significant margin misses in Q4FY25 despite higher other income and lower tax rates.

From Swiggy's widening net loss, Yes Bank's stake sale to Manappuram Finance's impairment charges, these are the important ...

Dr Reddy's posted consolidated net profit growth of 21 per cent year-on-year to Rs 1,587 crore during the March quarter, ...

Pharma major Dr Reddy’s Laboratories Ltd’s consolidated net profit increased 21% in the fourth quarter ended March 31, 2025 ...

Dr. Reddys Laboratories reported a 22% YoY rise in Q4 net profit to Rs 1,594 crore, exceeding estimates. Revenue grew 20% to ...

Dr. Reddy's Laboratories Ltd. closed 18.57% short of its 52-week high of 1,420.20 rupees, which the company achieved on ...

Markets top brokerage firms forecast suggest that Dr Reddys Laboratories will report a net profit of approximately Rs 1,456.5 ...

Dr. Reddy's Laboratories Ltd. closed 19.12% below its 52-week high of 1,420.20 rupees, which the company achieved on August ...

Hyderabad: Dr Reddy's Laboratories posted a consolidated 22% jump in profit after tax attributable to equity holders at Rs ...

Dr. Reddy's Laboratories, a global pharmaceutical company, recently closed in early 2025 due to business and financial ...

Dr. Reddy's Laboratories announced a 21% surge in net profit, reaching Rs 1,587 crore for the March 2025 quarter, fueled by strong sales in the US and India. Annual profit saw a modest 3% rise to ...

Dr Reddy's Laboratories recorded a 21% increase in net profit for the March quarter, reaching Rs 1,587 crore, supported by ...